Chiang H S, Wen T C, Wu C C, Chiang W H
Department of Urology, Taipei Medical College, Taiwan, R.O.C.
J Formos Med Assoc. 1992 Sep;91(9):898-901.
Fifty-one patients with chronic erectile dysfunction were selected for this study involving intracavernous self-injection therapy with papaverine or prostaglandin E1 (PGE1). Patients were screened and grouped as follows: pronounced vasculogenic, mild vasculogenic, venous leakage, neurogenic and psychogenic impotence. The duration of follow-up in these 51 patients was from 1.5-30.5 months (average, 11.8 months). The average effective dosage of papaverine and PGE1 was variable among the different groups. This kind of therapy proved to be effective in our preliminary results, which showed that 35 patients (68.6%) were found to be good responders and eight patients (15.7%) were temporary responders. In our detailed questionnaire, answered by all 51 patients, we found 29 patients (56.9%) had increased their frequency of sexual activity, 38 patients (74.5%) had sustained their erection more than they ever had before, and 43 patients (84.3%) had enjoyed sexual orgasm following this pharmacologically assisted erection. Compared with papaverine, PGE1 was found to have fewer complications. None of the patients complained of any discomfort after long-term, self-injection with PGE1. However, two patients (3.9%) had sustained erections and two patients (3.9%) developed palpable fibrotic plaque after papaverine injection in our study.
本研究选取了51例慢性勃起功能障碍患者，采用罂粟碱或前列腺素E1（PGE1）进行海绵体内自我注射治疗。患者经筛选后分组如下：明显血管源性、轻度血管源性、静脉漏、神经源性和心因性阳痿。这51例患者的随访时间为1.5 - 30.5个月（平均11.8个月）。不同组间罂粟碱和PGE1的平均有效剂量各不相同。初步结果表明，这种治疗方法是有效的，其中35例患者（68.6%）疗效良好，8例患者（15.7%）为暂时有效。在所有51例患者填写的详细问卷中，我们发现29例患者（56.9%）性活动频率增加，38例患者（74.5%）勃起维持时间比以往更长，43例患者（84.3%）在药物辅助勃起后有性高潮。与罂粟碱相比，PGE1的并发症更少。在我们的研究中，长期自我注射PGE1后，没有患者抱怨任何不适。然而，注射罂粟碱后，有2例患者（3.9%）出现持续性勃起，2例患者（3.9%）出现可触及的纤维化斑块。
